Avita Medical (RCEL) Stock Price, News & Analysis

Company Overview

Avita Medical, Inc. (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S. Food and Drug Administration for acute thermal burn wounds. The company has since expanded its clinical indications and market access efforts into regions such as Australia, China and other parts of Asia. Avita collaborates with leading burn centers, academic institutions and investigator‐initiated trials to explore additional applications—ranging from chronic diabetic ulcers to vitiligo and hair restoration.

Under the leadership of President and Chief Executive Officer Michael Perry, Avita Medical has emphasized the integration of its proprietary cell‐harvesting technology into standard burn and wound care protocols. The company maintains a global commercial infrastructure to support physician training, clinical research, and post‐market surveillance. Its strategic priorities include broadening clinical adoption of ReCell, pursuing new regulatory approvals and fostering partnerships to extend its regenerative platform into adjacent markets.

Key Stats

• Today's Range: $3.92 to $4.08
• 50-Day Range: $3.91 to $5.60
• 52-Week Range: $3.22 to $7.12
• Volume: 223,899 shs
• Average Volume: 218,668 shs
• Market Capitalization: $123.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.25
• Consensus Rating: Hold

Avita Medical Stock Analysis - MarketRank™

Avita Medical scored higher than 62% of companies evaluated by MarketBeat, and ranked 306th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Avita Medical has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Avita Medical has a consensus price target of $7.25, representing about 80.8% upside from its current price of $4.01.

Amount of Analyst Coverage

Avita Medical has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avita Medical are expected to grow in the coming year, from ($1.29) to ($1.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avita Medical is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avita Medical is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.03% of the float of Avita Medical has been sold short.

Short Interest Ratio / Days to Cover

Avita Medical has a short interest ratio ("days to cover") of 15.34, which indicates bearish sentiment.

Change versus previous month

Short interest in Avita Medical has recently decreased by 7.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avita Medical does not currently pay a dividend.

Dividend Growth

Avita Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Avita Medical this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for RCEL on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Avita Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 4.0 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Avita Medical in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $155,080.00 in company stock, which represents 0.1256% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Avita Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $155,080.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

2.80% of the stock of Avita Medical is held by insiders.

Percentage Held by Institutions

27.66% of the stock of Avita Medical is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/21/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:RCEL
• CIK: 1762303
• Web: www.avitamedical.com
• Phone: (833) 462-8482
• Fax: N/A
• Employees: 130
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Avita Medical: $7.25
• High Price Target: $10.00
• Low Price Target: $3.00
• Potential Upside/Downside: +80.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.59 million
• Net Margins: -62.67%
• Pretax Margin: -62.68%
• Return on Equity: N/A
• Return on Assets: -78.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.47
• Quick Ratio: 0.38

Sales & Book Value

• Annual Sales: $71.61 million
• Price / Sales: 1.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.55) per share
• Price / Book: -7.29

Miscellaneous

• Outstanding Shares: 30,780,000
• Free Float: 29,915,000
• Market Cap: $123.43 million
• Optionable: Optionable
• Beta: 1.87